Welcome to the e-CCO Library!

P402: Incidence and outcomes of herpes zoster in the ozanimod phase 3 ulcerative colitis and relapsing multiple sclerosis clinical program
Year: 2022
Source: ECCO'22
Authors: Siegmund, B.(1);Melmed, G.Y.(2);Irving, P.M.(3);Pai, A.(4);Patel, A.(4);Sheffield, J.K.(4);Caldera, F.(5);Cree, B.A.C.(6);Dubinsky, M.C.(7);
Created: Friday, 11 February 2022, 3:52 PM
P402: Interstitial and granulomatous lung disease in inflammatory bowel disease patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Eliadou1*, J. Moleiro2, D.G. Ribaldone3, M. Astegiano3, K. Rothfuß4, C. Taxonera5, B. Verstockt6, F. Ghalim7, F. Carbonnel7, S. Festa8, A. Berrozpe9, L. Maia10, E. Savarino11, P. Ellul12, E. Zagorowicz13, S. Vavricka14, M. Calvo15, I. Koutroubakis16, F. Hoentjen17, L. Fernández Salazar18, F. Callela19, F. Cañete Pizarro20, K. Soufleris21, E. Sonnenberg22, M. Cavicchi23, G. Fiorino24,25

Created: Thursday, 21 February 2019, 9:14 AM
P402: Is co-trimoxazole prophylaxis necessary for Inflammatory Bowel Disease patients receiving triple immunosuppression?
Year: 2021
Source: ECCO'21 Virtual
Authors: Phillips, G.(1);Moore-Gillan, C.(1);Mohamed, Z.(1);Mikin, P.(1);Peake, S.(1);Hicks, L.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P402: Systemic steroids vs. local acting steroids: Relative risk for corticosteroid-related adverse events
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Timeus1, R. Hofmann*2

Created: Friday, 22 February 2019, 9:41 AM
P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Sandborn1, E.V. Loftus Jr2, F. Baert3, J. Jansson4, J. Chen4, N. Candela5, K. Lasch5, K. Kisfalvi4

Created: Thursday, 30 January 2020, 10:12 AM
P403: Adherence to vaccination recommendations in patients with Inflammatory Bowel Disease: a long way for improving.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ferreiro Iglesias, R.(1);Hernández Camba, A.(2);Saldaña, R.(3);Rodríguez-Lago, I.(4);Zabana, Y.(5);Barreiro-de Acosta , M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P403: Combined therapy with anti-TNF and immunomodulator is superior to monotherapy for postoperative prophylaxis in Crohn’s disease after intestinal resection: a retrospective analysis from a tertiary centre
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. O’Connor*1, J. Taylor1, N. Scott2, C. Selinger1, J. Hamlin1, A. Ford1, 3

Created: Friday, 22 February 2019, 9:49 AM
P403: Golimumab therapy for ulcerative colitis – an Irish multicentre experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

O'Connell J.*1, Rowan C.2, Chan G.3, Harkin G.4, Parihar V.5, Layden J.3, Patchett S.5, Stack R.6, MacMathuna P.3, O'Toole A.5, Ryan B.7, MacCarthy F.1, McKiernan S.1, Doherty G.2, Eagan L.4, Kevans D.1

Created: Wednesday, 20 February 2019, 10:36 AM
P403: Intravenous iron infusion in inflammatory bowel disease: efficacy and ferro-economics
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Ranjan*1, D. Rayner1, F. Maw1, A. Dhar1

Created: Friday, 22 February 2019, 9:41 AM
P403: The role of Organic Cation Transporter (OCTN)-1 in predicting individual response to therapy in Ulcerative Colitis: towards a personalized approach.
Year: 2022
Source: ECCO'22
Authors: Puca, P.(1);Capobianco, I.(1);Petito, V.(1);Masi, L.(1);Fidaleo, M.(2);Del Chierico , F.(3);Palucci, I.(4);Lopetuso, L.R.(1);Laterza, L.(1);Settanni, C.R.(1);Parisio, L.(1);Bibbò, S.(1);Pugliese, D.(1);Armuzzi, A.(1);Pani, G.(5);Gasbarrini, A.(1);Scaldaferri, F.(1);
Created: Friday, 11 February 2022, 3:52 PM
P403: Therapeutic compliance in patients with chronic inflammatory bowel disease.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hajlaoui, A.(1)*;Sabbah, M.(2);Bibani, N.(2);Jlassi, H.(2);Bellil , N.(2);Lassoued, K.(2);Trad, D.(2);Gargouri, D.(2);
Created: Friday, 14 July 2023, 11:05 AM
P403: Treatment naïve newly diagnosed patients with Crohn's disease have microbial dysbiosis correlated with disease activity and faecal calprotectin—results from a prospective inception cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Yanai1,2*, I. Goren3,4, L. Reshef5, L. Godny1,2, K. Yadgar1, K. Zonenesain1, I. Dotan2,3

Created: Thursday, 21 February 2019, 9:14 AM
P404 Prolonged steroid exposure prior to admission is associated with increased likelihood of rescue therapy and colectomy in acute severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Barnes1,2, P. Spizzo1

Created: Thursday, 30 January 2020, 10:12 AM
P404: Development of anti-drug antibodies among those treated with adalimumab and ABP 501 and its impact on serum drug concentration in randomised controlled studies
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Chow*, A. Kaliyaperumal, N. Zhang, J. Miller, D. Mytych, M. Starcevic Manning, I. Wala, H. Wang, E. Krishnan

Created: Thursday, 21 February 2019, 9:14 AM
P404: Healthcare utilization and expenditures for patients with Ulcerative Colitis on advanced therapies in Germany
Year: 2021
Source: ECCO'21 Virtual
Authors: Picker, N.(1);Bokemeyer, B.(2);Wilke, T.(3);Rosin, L.(4);Patel, H.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P404: Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mathieu, N.(1)*;Riviere, P.(2); Heluwaert, F.(3); Hébuterne, X.(4);Chupin, A.(5);Bouguen, G.(6);Vuitton, L.(7);Allez, M.(8);Montuclard, C.(9);Nachury, M.(10);Nancey, S.(11);Amélie, B.(12); Gilletta, C.(13);Abitbol, V.(14);Altwegg, R.(15);de Maissin, A.(16);Plastaras , L.(17); Ah Soune, P.(18);Boureille, A.(19);Bouhnik, Y.(20);Seksik, P.(21);Chanteloup, E.(22);marion, S.(23);Uzzan, M.(24);Andrau, P.(25);Rouillon, C.(26);Arondel, Y.(27);Peyrin Biroulet, L.(28);Laharie, D.(29);
Created: Friday, 14 July 2023, 11:05 AM
P404: Real-life experience with golimumab in ulcerative colitis patients according to prior anti-TNF use
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Taxonera*1, F. Bertoletti2, C. Rodriguez3, I. Marin4, J. Arribas5, P. Martinez-Montiel6, M. Sierra7, L. Arias8, M. Rivero9, A. Juan10, E. Iglesias11, N. Manceñido12, J.L. Perez-Calle13, A. Algaba14, M. Barreiro-de Acosta15, A. Gutierrez16, F. Argüelles17, D. Busquets18, M. Chaparro19, C. Alba1, D. Olivares1, M. Calvo20, J.P. Gisbert19

Created: Friday, 22 February 2019, 9:49 AM
P404: Stopping 5-aminosalicylates in Crohn’s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Ungaro*1, B. Limketkai2, C. B. Jensen3, C. Yzet4, K. H. Allin3, M. Agrawal5, J. Burisch3, T. Ullman6, T. Jess3, J-F. Colombel1

Created: Friday, 22 February 2019, 9:41 AM
P404: Underrepresentation of minorities and lack of race reporting in ulcerative colitis drug development clinical trials
Year: 2022
Source: ECCO'22
Authors: Sedano, R.(1,2);Hogan, M.(3);McDonald, C.(4);Aswani-Omprakash, T.(5);Ma, C.(2,6);Jairath, V.(2,7);
Created: Friday, 11 February 2022, 3:52 PM
P404: Vaccinations and immunization status in Paediatric inflammatory bowel disease: data from the VIP IBD study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Martinelli M.*1, Strisciuglio C.2, Giugliano F.P.3, Urbonas V.4, Serban D.5, Banaszkiewicz A.6, Assa A.7, Drskova T.8, Hojsak I.9, Navas Lopez V.M.10, Romano C.11, Sladek M.12, Aloi M.13, Kucinskiene R.14, Staiano A.15, Miele E.15 ESPGHAN Open IBD Interest Group16

Created: Wednesday, 20 February 2019, 10:36 AM